Acquisition by Bobbi Brockmann of 4742 shares of ImmuCell at 3.15 subject to Rule 16b-3
| ICCC Stock | USD 6.19 0.06 0.96% |
About 62% of ImmuCell's investor base is looking to short. The analysis of overall sentiment of trading ImmuCell stock suggests that many investors are alarmed at this time. The current market sentiment, together with ImmuCell's historical and current headlines, can help investors time the market. In addition, many technical investors use ImmuCell stock news signals to limit their universe of possible portfolio assets.
Filed transaction by ImmuCell Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
ImmuCell Fundamental Analysis
We analyze ImmuCell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuCell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuCell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
ImmuCell is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
ImmuCell Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmuCell stock to make a market-neutral strategy. Peer analysis of ImmuCell could also be used in its relative valuation, which is a method of valuing ImmuCell by comparing valuation metrics with similar companies.
Peers
ImmuCell Related Equities
| MAIA | MAIA Biotechnology | 3.95 | ||||
| CSBR | Champions Oncology | 3.57 | ||||
| IRIX | IRIDEX | 3.13 | ||||
| NAII | Natural Alternatives | 1.11 | ||||
| TRGNF | Transgene | 0.00 |
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |